SSGJ-610 / 3SBio - LARVOL DELTA

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma (clinicaltrials.gov) - P2 | N=225 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and Safety Study of 610 in Patients With Severe Asthma (clinicaltrials.gov) - P3 | N=480 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth (PRNewswire) - "In 2020, the Company obtained three new IND approvals....610, an anti-IL5 antibody, obtained the IND approval from the NMPA for the treatment of severe eosinophilic asthma....For 610, the dose-escalating phase I clinical trial in healthy volunteers was completed."

Trial completion • Asthma • Respiratory Diseases